Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

June 19, 2026 updated by: CellCentric Ltd.

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This includes patients with Peripheral T-cell lymphoma.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
250

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • France
      • Bordeaux, France, 33076
        • Completed
        • Institute Bergonié
      • Villejuif, France, 94805
        • Completed
        • Gustave Roussy
  • Spain
      • Badalona, Spain, 08916
        • Recruiting
        • Hospital Germans Trias i Pujol/ ICO Badalona
        • Contact:
          • Albert Oriol-Rocafiguera
      • Barcelona, Spain, 08036
        • Recruiting
        • Hospital Clinic de Barcelona
        • Contact:
          • Laura Rosiñol Dachs
      • Barcelona, Spain, 08035
        • Completed
        • University Hospital Vall d'Hebron
      • Barcelona, Spain, 08908
        • Recruiting
        • ICO L'Hospitalet (Instituto Catalán de Oncología)
        • Contact:
          • Anna Sureda Balari
      • Madrid, Spain, 28034
        • Recruiting
        • Hospital Universitario Ramon y Cajal
        • Contact:
          • María J Blanchard Rodriguez
      • Madrid, Spain, 28041
        • Recruiting
        • Hospital Universitario 12 de Octubre
        • Contact:
          • Joaquin Martinez-Lopez
      • Madrid, Spain, 28006
        • Recruiting
        • Hospital Universitario de La Princesa
        • Contact:
          • Adrian Alegre Amor
      • Madrid, Spain, 28031
        • Recruiting
        • Hospital Infanta Leonor
        • Contact:
          • Jose Angel Hernandez- Rivas
      • Madrid, Spain, 28009
        • Recruiting
        • Hospital Universitario Gregorio Marañón
        • Contact:
          • Cristina Encinas Rodriguez
      • Madrid, Spain, 28050
        • Completed
        • CIOCC Hospital Universitario HM Sanchinarro
      • Pamplona, Spain, 31008
        • Recruiting
        • Universidad de Navarra
        • Contact:
          • Paula Rodriguez-Otero
      • Valencia, Spain, 46026
        • Recruiting
        • Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana
        • Contact:
          • Javier de la Rubia Comos
  • Sweden
      • Stockholm, Sweden
        • Completed
        • Karolinska Comprehensive Cancer Center
  • United Kingdom
      • Bebington, United Kingdom, CH63 4JY
        • Recruiting
        • The Clatterbridge Cancer Centre NHS Foundation Trust,
        • Contact:
        • Principal Investigator:
          • Gillian Brearton, MD
      • Bristol, United Kingdom
        • Recruiting
        • University Hospitals Bristol
        • Contact:
      • Cardiff, United Kingdom
        • Recruiting
        • University Hospital of Wales
        • Contact:
          • Steven Knapper
      • Derby, United Kingdom, DE22 3NE
        • Recruiting
        • Royal Derby Hospital
        • Contact:
        • Principal Investigator:
          • Firas Al-Kaisi, MD
      • Edinburgh, United Kingdom, EH4 2XU
        • Recruiting
        • Western General Hospital
        • Contact:
          • Victoria Campbell
      • Glasgow, United Kingdom, G12 0YN
        • Recruiting
        • Gartnavel General Hospital
        • Contact:
          • Jennifer Travers
      • Leicester, United Kingdom
        • Recruiting
        • Leicester Royal Infirmary
        • Contact:
          • Harriet Walter
      • London, United Kingdom, W1G 6AD
        • Recruiting
        • Sarah Cannon Research Institute UK
        • Contact:
          • Richard Dillon
      • London, United Kingdom
      • London, United Kingdom, EC1A 7BE
        • Recruiting
        • St Bartholomew's Hospital
        • Contact:
          • Heather Oakervee
      • London, United Kingdom, W1T 7HA
        • Recruiting
        • NIHR University College London Clinical Research Facility
        • Contact:
          • Jenny O'Nions
      • Manchester, United Kingdom
        • Recruiting
        • The Christie Hospital
        • Contact:
          • Tim Somervaille
      • Newcastle upon Tyne, United Kingdom
      • Nottingham, United Kingdom, NG5 1PB
        • Recruiting
        • Nottingham University Hospitals NHS Trust
        • Contact:
          • Dean Smith
      • Oxford, United Kingdom, OX3 7LE
        • Recruiting
        • Cancer and Haematology Centre
        • Contact:
          • Sarah Gooding
      • Southampton, United Kingdom, SO16 6YD
        • Recruiting
        • University Hospital of Southampton
        • Contact:
          • Andy Davies
      • Stoke-on-Trent, United Kingdom, ST4 6QG
        • Recruiting
        • Royal Stoke University Hospital
        • Contact:
          • Kamaraj Karunanithi
    • Surrey
      • Sutton, Surrey, United Kingdom, SM2 5PT
        • Recruiting
        • The Royal Marsden
        • Contact:
          • Charlotte Pawlyn
  • United States
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Recruiting
        • Emory Winship Cancer Institute
        • Principal Investigator:
          • Dr Nisha Joseph, MD
        • Contact:
    • Indiana
      • Indianapolis, Indiana, United States, 46227
        • Recruiting
        • Community Health Network
        • Contact:
        • Principal Investigator:
          • Pablo M Bedano, MD
    • Maryland
      • Bethesda, Maryland, United States, 20817
        • Recruiting
        • The Center for Cancer and Blood Disorders (CCBD)
        • Contact:
        • Principal Investigator:
          • Victor Priego, MD
    • Nebraska
      • Omaha, Nebraska, United States, 68130
        • Recruiting
        • Nebraska Cancer Specialists
        • Principal Investigator:
          • Stefano Tarantolo, MD
        • Contact:
      • Omaha, Nebraska, United States, 68198-6846
        • Recruiting
        • University of Nebraska Medical Center
        • Principal Investigator:
          • Sarah Holstein, MD
        • Contact:
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • Penn Medicine - Abramson Cancer Center Perelman
        • Contact:
        • Principal Investigator:
          • Dan Vogl, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Provision of consent
  • ECOG performance status 0-2
  • Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
  • Must have previously received standard therapy
  • Adequate organ function

Exclusion Criteria:

  • Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
  • Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
  • Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
  • Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
  • Patients should discontinue statins prior to starting study treatment
  • CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
  • Any unresolved reversible toxicities from prior therapy >CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
  • Any evidence of severe or uncontrolled systemic diseases
  • Any known uncontrolled inter-current illness
  • QTcF prolongation (> 470 msec)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: CCS1477 dose escalation NHL/MM
CCS1477 monotherapy
Drug: CCS1477
Oral capsule
Experimental: CCS1477 dose escalation AML/Higher risk MDS
CCS1477 monotherapy
Drug: CCS1477
Oral capsule
Experimental: CCS1477 monotherapy expansion and combination dose finding and expansion - AML
CCS1477 monotherapy, CCS1477 combination with azacitidine, CCS1477 combination with azacitidine and venetoclax
Drug: Venetoclax
Oral tablet
Drug: CCS1477
Oral capsule
Drug: Azacitidine
Powder suspension for Injection
Experimental: CCS1477 monotherapy expansion and combination dose finding and expansion NHL
CCS1477 monotherapy, CCS1477 combination with lenalidomide
Drug: Lenalidomide
Oral capsule
Drug: CCS1477
Oral capsule
Experimental: CCS1477 monotherapy expansion and combination dose finding and expansion - MM
CCS1477 monotherapy, CCS1477 combination with pomalidomide-dexamethasone, CCS1477 combination with bortezomib-dexamethasone, CCS1477 combination with ixazomib-dexamethasone, CCS1477 combination with elranatamab, CCS1477 combination with teclistamab, CCS1477 combination with lenalidomide, CCS1477 combination with lenalidomide and daratumumab
Drug: Lenalidomide
Oral capsule
Drug: Ixazomib
Oral capsule
Drug: CCS1477
Oral capsule
Drug: Pomalidomide
oral capsule
Drug: Dexamethasone
oral tablet
Drug: Bortezomib
Powder for solution for injection
Drug: Elranatamab
Solution for injection
Other Names:
  • Elrexfio
Drug: Teclistamab
Solution for injection
Other Names:
  • Tecvayli
Drug: Daratumumab
Solution for injection, concentrate for solution for infusion
Experimental: CCS1477 monotherapy expansion and combination dose finding and expansion - Higher risk MDS
CCS1477 monotherapy, CCS1477 combination with azacitidine
Drug: CCS1477
Oral capsule
Drug: Azacitidine
Powder suspension for Injection

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Incidence of treatment-related adverse events
Time Frame: Up to 12 months
Treatment-related adverse events and serious adverse events
Up to 12 months
Incidence of laboratory abnormalities
Time Frame: Up to 12 months
Laboratory abnormalities characterised by type, frequency, severity and timing
Up to 12 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Response rate
Time Frame: Up to 12 months

Defined as number of patients who have a response according to

  • RECIL criteria (NHL)
  • IMWG criteria (Multiple myeloma)
  • ELN recommendations 2017 (AML)
Up to 12 months
Duration of Response
Time Frame: Up to 12 months
Defined as the time from start of treatment until disease progression
Up to 12 months
AUC of CCS1477
Time Frame: 35 days
Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration of CCS1477
35 days
Cmax of CCS1477
Time Frame: 35 days
Maximum observed plasma concentration (Cmax) of CCS1477
35 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
CellCentric Ltd.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Tim Somervaille, The Christie NHS Foundation Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 9, 2019

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 31, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 31, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 12, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 22, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 28, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 24, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 19, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CCS1477-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

At this stage, is not currently planned that any IPD information will be shared with other researchers outside of the Sponsor and Clinical Research Organisations involved in the conduct of this study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings